Clinical trials: Atopic Eczema
Atopic Dermatitis
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)
This is multi-center, randomized, double-blind, parallel, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis
- Trial name
- NCT03269773
- Testing
- FURESTEM-AD Inj.
- Where
- 11 sites in South Korea
- Volunteers
- 197 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Dermatitis, Atopic
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2%…
- Trial name
- NCT03233529
- Testing
- Crisaborole ointment 2% BID
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pfizer
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Conditions
- Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic
- Trial name
- NCT03054428
- Testing
- Dupilumab
- Where
- 45 sites in United States, Canada
- Volunteers
- 251 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Eczema
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT02871479
- Testing
- SAN007 5% cream, SAN007 10% cream
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Dermatitis, Atopic
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult…
- Trial name
- NCT02655679
- Testing
- VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
- Where
- 12 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Atopic Dermatitis
A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT03000595
- Testing
- SAN007 Cream
- Sponsor
- Santalis Pharmaceuticals, Inc.
Atopic Dermatitis, Eczema
A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03089229
- Testing
- HAT01H Cream, Vehicle Cream
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Haus Bioceuticals
Atopic Dermatitis, Eczema, Atopic
A Study in Subjects With Moderate Atopic Dermatitis
This is a randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of ALX-101 Gel 1.5% and 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 42 days to adult and adolescent…
- Trial name
- NCT03175354
- Testing
- ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Ralexar Therapeutics, Inc.
Atopic Dermatitis
Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo on change from baseline in Total Lesion Symptom Score in subjects with mild to…
- Trial name
- KINSHIP (NCT02324972)
- Testing
- AQX-1125
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Atopic Disorders, Eczema, Atopic
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).
- Trial name
- NCT03050151
- Testing
- Dupilumab, Auto-injector Device, Prefilled syringe
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
DMT210 Topical Gel in the Treatment of Atopic Dermatitis
The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild…
- Trial name
- NCT02949960
- Testing
- DMT210 Topical Gel, Vehicle Control
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dermata Therapeutics
Atopic Dermatitis
Topical Solution for the Treatment of Atopic Dermatitis
The study is designed as a proof of concept, multi-center, randomized, double-blind and vehicle-controlled study with intra-individual comparison of treatments.
- Trial name
- CYCLATOP (NCT02865356)
- Testing
- Cyclosporine 5% solution
- Where
- 9 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Spherium Biomed
Chronic Eczema, Psoriasis
Revitalization of Damaged Skin Due to Chronic Skin Diseases
Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture…
- Conditions
- Chronic Eczema, Psoriasis, Atopic Dermatitis
- Trial name
- NCT03485560
- Testing
- ACE CSD
- Where
- 2 sites in Serbia, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Ace Cells Lab Limited
Atopic Dermatitis
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
- Trial name
- ALLEVIAD (NCT02525094)
- Testing
- MEDI9929
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis Eczema
Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.
The purpose of this study is to observe the performance of a cosmetic product, AO+Mist, on the appearance of arm skin in subjects with atopic dermatitis
- Trial name
- NCT03268174
- Testing
- AO+Mist
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AOBiome LLC
Atopic Dermatitis
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01859988
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 380 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children
The purpose of this study was to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in…
- Trial name
- NCT00886587
- Testing
- F# 11054-010, F# 10495-053
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Eczema
Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin
The purpose of this 3 week study is to test the effectiveness of an over-the-counter (OTC) skin balm in infants and toddlers with mild to moderate dry, itchy skin.
- Trial name
- NCT02404493
- Testing
- EpiCeram Skin Barrier Emulsion, 1% Colloidal Oatmeal Balm
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Pruritus in Patients With Atopic Dermatitis
Safety and Efficacy of DNK333 in Atopic Dermatitis Patients
This study will assess the safety and efficacy of DNK333 in patients with atopic dermatitis suffering from pruritus, who require systemic treatment of the disease.
- Trial name
- NCT01033097
- Testing
- DNK333 5 mg, DNK333 25 mg, DNK333 100 mg
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
The objective of this 1 week trial is to evaluate the efficacy of an over-the-counter (OTC) 1% colloidal oatmeal skin protectant cream in adults and children with mild to moderate AD.
- Trial name
- NCT02691507
- Testing
- EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)